A man in his 70s with breast cancer experienced a rare and deadly lung complication called pulmonary tumor thrombotic microangiopathy (PTTM), a condition that is seldom seen, especially in men. PTTM often causes rapidly worsening breathing problems and right heart failure, typically leading to death within a short period. While PTTM has been reported with several cancers, its occurrence in male breast cancer patients is extremely unusual.
The patient, diagnosed with hormone receptor-positive invasive ductal carcinoma in his right breast, had undergone surgery and was receiving chemotherapy when he began to feel increasingly breathless. Despite his treatment history and ongoing monitoring, his symptoms quickly escalated. Although imaging showed no classic lung blood clots, and further CT scans did not find evidence of pulmonary embolism, he soon developed acute respiratory failure and right heart failure. The patient passed away shortly after being admitted to the hospital.
Autopsy findings revealed that the small arteries in his lungs were blocked by cancer cells, causing thickening and blood clots within the vessels—features characteristic of PTTM. The cancer had spread to several other organs, including the lymph nodes, liver, bone marrow, small intestine, and adrenal glands, although some of these metastases were not visible on CT scans before his death.
PTTM is largely underdiagnosed during life because its symptoms mimic common lung and heart conditions, and it tends to progress rapidly. Even advanced imaging techniques may not always detect it, as findings are not always specific to this disorder. In most cases, the diagnosis is only confirmed after the patient has died.
Experts highlight the importance of considering PTTM in cancer patients, even in those with rare cancers like male breast cancer, especially when breathing problems worsen quickly and do not fit the usual causes. Early suspicion might offer a small chance for doctors to adjust treatment, but outcomes remain very poor. This case draws attention to the need for awareness of such rare complications in all breast cancer patients, regardless of gender.
